Sutro Biopharma, Inc. (STRO)

Over the past six months, Sutro Biopharma's stock price has experienced significant movement. As of April 11, 2026, the stock's price increased by 329.28% over the last 12 months, with a year-to-date return of 123.51%. In the past month, the stock increased by 5.38%. Key events include reporting Q3 2025 financial results and FDA clearance for STRO-004 in November 2025, participation in the JP Morgan Healthcare Conference in January 2026, and reporting full year 2025 financial results in March 2026, with revenue growth due to collaborations. The company also announced a $110 million equity financing, extending its cash runway. Analyst upgrades from HC Wainwright & Co. and Wells Fargo, and Leerink initiated coverage with an Outperform rating.

Demand seasonality is not directly applicable to Sutro Biopharma, Inc., as a clinical-stage biotechnology company. Demand for its product candidates is driven by unmet medical needs in cancer treatment and the progression of clinical trials and regulatory approvals, rather than seasonal consumer patterns.

Sutro Biopharma, Inc. is a clinical-stage oncology company focused on discovering, developing, and manufacturing cancer therapeutics. They utilize their XpressCF® and XpressCF+® platforms to create next-generation protein therapeutics, including antibody-drug conjugates (ADCs), cytokine-based immuno-oncology therapies, and bispecific antibodies. Sutro's pipeline includes STRO-001, a CD74-targeting ADC; STRO-002 (luvelta), a folate receptor alpha (FolRα)-targeting ADC; STRO-003, a ROR1-targeting ADC; STRO-004, a tissue factor (TF)-targeting exatecan ADC; STRO-006, a highly selective integrin β6 (ITGB6) ADC; STRO-227, a dual-payload ADC candidate targeting tyrosine-protein kinase-like 7 (PTK7); MK-1484, a selective IL-2 agonist; an immunostimulatory ADC (iADC); and VAX-24 and VAX-31, pneumococcal conjugate vaccine candidates.

Sutro Biopharma, Inc. is headquartered in South San Francisco, California, and has a cGMP manufacturing facility in San Carlos, California. Its operations are primarily based in the San Francisco Bay Area.

Sutro Biopharma's brand reputation appears positive, driven by advancements in its ADC platform, clinical trial progress, and strategic collaborations. The company's focus on innovative technology, regular updates on clinical-stage candidates, and collaborations with major pharmaceutical companies contribute to this positive perception. A successful equity offering and analyst upgrades further enhance its reputation. Participation in industry conferences also helps maintain visibility.

Sutro Biopharma, Inc. has a significant institutional ownership presence. As of April 8, 2026, 59 institutional owners and shareholders have filed 13D/G or 13F forms, holding a total of 5,308,512 shares. Major institutional owners include Affinity Asset Advisors, LLC, Kynam Capital Management, LP, Millennium Management Llc, Vanguard Group Inc, Acadian Asset Management Llc, Velan Capital Investment Management LP, Vestal Point Capital, LP, Balyasny Asset Management Llc, Samsara BioCapital, LLC, Adage Capital Partners Gp, L.l.c., BVF Partners LP, Merck & Co., Inc., BlackRock, Inc., Opaleye Management Inc., Point72 Asset Management, L.P., RA Capital Management, L.P., Goldman Sachs Group Inc., Geode Capital Management LLC, Fisher Asset Management LLC, JPMorgan Chase & Co., and Prudential Financial Inc. Major individual and insider owners include Merck Co Inc, Skyline Venture Partners V LP, Alta Partners VIII LP, Daniel Janney, Svlsf V LLC, Michael Jay Ross, Celgene Corp, and William J. Newell (CEO).